AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19448846 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonresponders)
Number of subjects: 24
Study 17146730 — intervention group
Group type: EXPERIMENTAL
Intervention: Indibulin 20 mg (fed condition)
Number of subjects: 14
Study 17146730 — intervention group
Group type: EXPERIMENTAL
Intervention: Indibulin 20 mg (fasted condition)
Number of subjects: 14
Study 17146730 — intervention group
Group type: EXPERIMENTAL
Intervention: Indibulin (dose escalation study)
Number of subjects: 14
Study 17146730 — intervention group
Group type: EXPERIMENTAL
Intervention: Indibulin 60 mg (recommended dose level)
Number of subjects: 14
Study 15794406 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Number of subjects: 45
Study 15794406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 45
Study 15794406 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 45
Study 11354519 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-beta-estradiol (E2) administration (100 microg.d(‐1) x 3.5d -> 200 microg.d(‐1) x 3.5 d -> 300 microg.d(‐1) x 4.0 d)
Number of subjects: 11
Study 11354519 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-beta-estradiol (E2) administration
Number of subjects: 11
Study 11354519 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 11
Study 10958250 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (oral doses of 10-40 mg/day)
Number of subjects: 13
Study 10958250 — intervention group
Group type: COMPARATOR
Intervention: Propanteline (active placebo)
Number of subjects: 13
Study 8291818 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice guideline recommendation with concurrent reminders
Number of subjects: 375
Study 8291818 — intervention group
Group type: COMPARATOR
Intervention: Control group (no concurrent reminders)
Number of subjects: 375
Study 3354489 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation in American women
Number of subjects: 0
Study 3354489 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented American and Egyptian women
Number of subjects: 0
Study 3354489 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium levels in milk
Number of subjects: 0
Study 3354489 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium levels in milk
Number of subjects: 0
Study 3354489 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc levels in milk
Number of subjects: 0
Study 29739677 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g soy protein with 66 mg isoflavone (SPI)
Number of subjects: 200
Study 29739677 — intervention group
Group type: COMPARATOR
Intervention: 15 g soy protein alone (SP)
Number of subjects: 200
Study 27325551 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 82
Study 27325551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 25794517 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 2148
Study 25794517 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2148
Study 24304002 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc (recombinant factor IX Fc fusion protein) administered weekly (50 IU/kg)
Number of subjects: 123
Study 24304002 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc (recombinant factor IX Fc fusion protein) administered every 10 days (100 IU/kg)
Number of subjects: 123
Study 24304002 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc (recombinant factor IX Fc fusion protein) administered as needed for bleeding episodes (20 to 100 IU/kg)
Number of subjects: 123
Study 24304002 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc (recombinant factor IX Fc fusion protein) for perioperative treatment
Number of subjects: 123
Study 24304002 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc (recombinant factor IX Fc fusion protein)
Number of subjects: 123
Study 21228266 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein meal
Number of subjects: 23
Study 21228266 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein protein meal
Number of subjects: 23
Study 21228266 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein meal
Number of subjects: 23
Study 21228266 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate meal
Number of subjects: 23
Study 21228266 — intervention group
Group type: COMPARATOR
Intervention: Glucose meal
Number of subjects: 23
Study 21228266 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein and Soy protein meals
Number of subjects: 23
Study 17980878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test before IVF cycle
Number of subjects: 280
Study 17228986 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty management intervention delivered during 4 weekly telephone sessions using audiotaped cognitive-behavioral strategies and a self-help manual.
Number of subjects: 483
Study 17228986 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty management intervention
Number of subjects: 483
Study 17228986 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 483
Study 12846911 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiDex (tissue-engineered autologous epidermal equivalent derived from outer root sheath keratinocytes)
Number of subjects: 0
Study 12846911 — intervention group
Group type: COMPARATOR
Intervention: Split-thickness skin autografting
Number of subjects: 0
Study 10632652 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg b.d.), clarithromycin (500 mg b.d.), amoxycillin (1 g b.d.) for 10 days (OAC)
Number of subjects: 104
Study 10632652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (400 mg b.d.), clarithromycin (500 mg b.d.), amoxycillin (1 g b.d.) for 10 days (RAC)
Number of subjects: 104
Study 9368169 — intervention group
Group type: EXPERIMENTAL
Intervention: HsS (elastoviscous hylan surgical shield, 0.45%)
Number of subjects: 60
Study 9368169 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution
Number of subjects: 60
Study 8238713 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized warm‐up, cool-down, and stretching exercises
Number of subjects: 421
Study 8238713 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 421
Study 3310827 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.150 mg levonorgestrel plus 0.030 mg ethinyloestradiol
Number of subjects: 20
Study 3310827 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.150 mg desogestrel plus 0.030 mg ethinyloestradiol
Number of subjects: 20
Study 29690966 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb ergometer exercise for 8 weeks, 4 days/week
Number of subjects: 60
Study 29690966 — intervention group
Group type: COMPARATOR
Intervention: Non-trained control group
Number of subjects: 60
Study 27042166 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermogenic fat loss supplement (TFLS)
Number of subjects: 10
Study 27042166 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 26609745 — intervention group
Group type: EXPERIMENTAL
Intervention: Great Users (17.2% of participants); high mean and level, no slope
Number of subjects: 161
Study 26609745 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Users (32.8% of participants); moderate mean and level, no slope
Number of subjects: 161
Study 26609745 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Users (22.7% of participants); low mean and level, negative slope
Number of subjects: 161
Study 26609745 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Decliners; moderate mean and level, negative slope, high variance
Number of subjects: 161
Study 23533232 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Number of subjects: 111
Study 23533232 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate with increased protein diet
Number of subjects: 111
Study 23533232 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diet groups
Number of subjects: 111
Study 20679593 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with 75% expectation of receiving active medication
Number of subjects: 35
Study 20679593 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with 25%, 50%, or 100% expectation of receiving active medication
Number of subjects: 35
Study 20679593 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 35
Study 20679593 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of clinical improvement
Number of subjects: 35
Study 20679593 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior medication response
Number of subjects: 35
Study 19086719 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS index monitoring
Number of subjects: 35
Study 19086719 — intervention group
Group type: EXPERIMENTAL
Intervention: AEP monitor
Number of subjects: 35
Study 19086719 — intervention group
Group type: COMPARATOR
Intervention: Standard procedures (control group)
Number of subjects: 35
Study 19086719 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS index and AEP monitor
Number of subjects: 35
Study 19034458 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided percutaneous nephrostomy (PCN) using a MRI-compatible drainage kit and Seldinger technique
Number of subjects: 8
Study 19034458 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided percutaneous nephrostomy (PCN) in dilated renal collection systems
Number of subjects: 8
Study 19034458 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided percutaneous nephrostomy (PCN)
Number of subjects: 8
Study 15084996 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 150
Study 15084996 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 150
Study 15084996 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch therapy
Number of subjects: 150
Study 15084996 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote intercessory prayer
Number of subjects: 150
Study 15084996 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 150
Study 11562517 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation programme (18 visits over 6 weeks)
Number of subjects: 200
Study 11562517 — intervention group
Group type: COMPARATOR
Intervention: Standard medical management
Number of subjects: 200
Study 9784908 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 38
Study 9784908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 8164818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 43
Study 8164818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 3280999 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy for 12 months (Group A)
Number of subjects: 48
Study 3280999 — intervention group
Group type: COMPARATOR
Intervention: Infant stimulation for 6 months followed by physical therapy for 6 months (Group B)
Number of subjects: 48
Study 31501052 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled POL6014 (doses 80 to 320 mg in subjects with CF)
Number of subjects: 0
Study 31501052 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled POL6014 (doses 20 to 960 mg in healthy volunteers)
Number of subjects: 0
Study 31117835 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 21
Study 31117835 — intervention group
Group type: COMPARATOR
Intervention: Matched controls without heart failure or ischemic heart disease
Number of subjects: 21
Study 28377422 — intervention group
Group type: EXPERIMENTAL
Intervention: Offer of a free self-sampling kit online
Number of subjects: 11075
Study 28377422 — intervention group
Group type: COMPARATOR
Intervention: Control group (invited to be screened in primary care settings)
Number of subjects: 11075
Study 25170252 — intervention group
Group type: EXPERIMENTAL
Intervention: ER OC/APAP following a high-fat meal
Number of subjects: 48
Study 25170252 — intervention group
Group type: EXPERIMENTAL
Intervention: ER OC/APAP following a low-fat meal
Number of subjects: 48
Study 25170252 — intervention group
Group type: EXPERIMENTAL
Intervention: ER OC/APAP under fasted conditions
Number of subjects: 48
Study 21958742 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical angina
Number of subjects: 2319
Study 21958742 — intervention group
Group type: EXPERIMENTAL
Intervention: Anginal equivalents
Number of subjects: 2319
Study 21958742 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of symptoms
Number of subjects: 2319
Study 21958742 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic
Number of subjects: 2319
Study 21958742 — intervention group
Group type: EXPERIMENTAL
Intervention: History of β-blocker use
Number of subjects: 2319
Study 21958742 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous percutaneous coronary intervention
Number of subjects: 2319
Study 20002087 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ritonavir (three oral doses of 100 mg over 24 h)
Number of subjects: 13
Study 20002087 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT-2074 (three oral doses of 80 mg over 24 h)
Number of subjects: 13
Study 17284131 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75-225 mg/day)
Number of subjects: 169
Study 17284131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 17284131 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 169
Study 15113944 — intervention group
Group type: EXPERIMENTAL
Intervention: Test fat F (5 g/100 g long chain (n‐3) fatty acids)
Number of subjects: 16
Study 15113944 — intervention group
Group type: EXPERIMENTAL
Intervention: Test fat F
Number of subjects: 16
Study 15113944 — intervention group
Group type: COMPARATOR
Intervention: Test fat O
Number of subjects: 16
Study 12575603 — intervention group
Group type: EXPERIMENTAL
Intervention: Liandai Capsule
Number of subjects: 45
Study 12575603 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 9563534 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplements (30 g/day)
Number of subjects: 13
Study 9563534 — intervention group
Group type: COMPARATOR
Intervention: Control (no glutamine)
Number of subjects: 13
Study 7889887 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg boron/day supplement
Number of subjects: 20
Study 7889887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2979275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg daily)
Number of subjects: 0
Study 2979275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg daily)
Number of subjects: 0
Study 2979275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2979275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and Ranitidine
Number of subjects: 0
Study 30246749 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel crown restoration
Number of subjects: 60
Study 30246749 — intervention group
Group type: COMPARATOR
Intervention: Unrestored contralateral teeth
Number of subjects: 60
Study 27302483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ERCP
Number of subjects: 104
Study 27302483 — intervention group
Group type: COMPARATOR
Intervention: LBDE
Number of subjects: 104
Study 24962480 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligonol (200 mg daily for 1 week)
Number of subjects: 19
Study 22591964 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 100
Study 22591964 — intervention group
Group type: COMPARATOR
Intervention: Nephrostomy tube
Number of subjects: 100
Study 19940348 — intervention group
Group type: EXPERIMENTAL
Intervention: iButtons
Number of subjects: 8
Study 19940348 — intervention group
Group type: COMPARATOR
Intervention: thermistors
Number of subjects: 8
Study 19940348 — intervention group
Group type: EXPERIMENTAL
Intervention: iButtons and thermistors
Number of subjects: 8
Study 18394829 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day oral dehydroepiandrosterone (DHEA)
Number of subjects: 32
Study 18394829 — intervention group
Group type: COMPARATOR
Intervention: 50 microg transdermal estradiol plus 100 mg/day oral micronized progesterone (HRT)
Number of subjects: 32
Study 18394829 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA plus HRT
Number of subjects: 32
Study 18394829 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA, HRT, and DHEA plus HRT
Number of subjects: 32
Study 16126372 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg DHEA
Number of subjects: 0
Study 16126372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16126372 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 0
Study 12546172 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 67
Study 12546172 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 67
Study 10659896 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 microg per vagina every 4 h as needed
Number of subjects: 91
Study 10659896 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (intravenous)
Number of subjects: 91
Study 7624736 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g n‐3 PUFAs daily for 6 weeks
Number of subjects: 46
Study 7624736 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65 g n‐3 PUFAs daily for 6 weeks
Number of subjects: 46
Study 7624736 — intervention group
Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 46
Study 2612495 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (Lamictal) as add-on therapy
Number of subjects: 34
Study 2612495 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 34
Study 944387 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa
Number of subjects: 100
Study 944387 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa with L-tryptophan
Number of subjects: 100
Study 944387 — intervention group
Group type: EXPERIMENTAL
Intervention: withdrawal from levodopa
Number of subjects: 100
Study 29093159 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTO6785 15, 50, 100, or 200 mg every 4 weeks + MTX
Number of subjects: 0
Study 29093159 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MTX
Number of subjects: 0
Study 27552276 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-biased desks for 2 consecutive years
Number of subjects: 380
Study 27552276 — intervention group
Group type: COMPARATOR
Intervention: Standard desks during both years
Number of subjects: 380
Study 24534270 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated brisk walking (3 × 10 minutes, 5 days/week) with telephone support
Number of subjects: 77
Study 24534270 — intervention group
Group type: COMPARATOR
Intervention: Control group performing stretching exercises
Number of subjects: 77
Study 22505632 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (7 days of intravenous administration)
Number of subjects: 52
Study 22505632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 20518927 — intervention group
Group type: COMPARATOR
Intervention: Control (G1 - sound teeth)
Number of subjects: 90
Study 20518927 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD cavity preparation (G2)
Number of subjects: 90
Study 20518927 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD + root canal treatment (G3)
Number of subjects: 90
Study 20518927 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD + Endo + composite resin restoration (G4)
Number of subjects: 90
Study 20518927 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD + Endo + unidirectional fibre + Resin (G5)
Number of subjects: 90
Study 20518927 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD + Endo + woven fibre + Resin (G6)
Number of subjects: 90
Study 18291724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam (LEV)
Number of subjects: 50
Study 15969830 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult guidance
Number of subjects: 0
Study 15969830 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer discussion
Number of subjects: 0
Study 15969830 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-child condition
Number of subjects: 0
Study 15969830 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 0
Study 14569170 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 49
Study 14569170 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (Control)
Number of subjects: 49
Study 14569170 — intervention group
Group type: COMPARATOR
Intervention: 201Tl rest
Number of subjects: 49
Study 14569170 — intervention group
Group type: COMPARATOR
Intervention: 201Tl redistribution
Number of subjects: 49
Study 14569170 — intervention group
Group type: COMPARATOR
Intervention: 18F-FDG
Number of subjects: 49
Study 14569170 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography (Revascularized patients)
Number of subjects: 49
Study 10919601 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mM supplemental GSH to perfusate
Number of subjects: 100
Study 10919601 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control)
Number of subjects: 100
Study 10919601 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine perfusion (MP) in UW-machine perfusate solution (MPS)
Number of subjects: 100
Study 10919601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold storage (CS) in UW
Number of subjects: 100
Study 9344049 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperactive group (HA)
Number of subjects: 4
Study 9344049 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperactive/conduct-disordered group (HA+CD)
Number of subjects: 4
Study 9344049 — intervention group
Group type: EXPERIMENTAL
Intervention: Conduct-disordered group (CD)
Number of subjects: 4
Study 9344049 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (N)
Number of subjects: 4
Study 8229721 — intervention group
Group type: EXPERIMENTAL
Intervention: True Vista bifocal IOL
Number of subjects: 446
Study 3542325 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (250 mg)
Number of subjects: 115